Monistat 1 OTC Switch May Help J&J Gain Feminine Category Lead
This article was originally published in The Tan Sheet
Executive Summary
J&J Personal Products could overtake private labelers in the yeast infection treatment market when it introduces its recently approved Monistat 1 combination pack.
You may also be interested in...
Johnson & Johnson President Brings Extensive McNeil Background To Post
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
Monistat Labeling To Carry Vaginal Miconazole/Warfarin Interaction Warning
Johnson & Johnson Personal Products will update the labeling for its miconazole-containing Monistat 3 and Monistat 7 yeast infection treatments within the year to note the possible interaction between vaginal miconazole and the Rx blood-thinning medication warfarin.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC